Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment

Fig. 3

Kaplan–Meier curves for PFS. The median PFS was 4.5 months (95% CI, 3.5–5.7) for OSI and 3.9 months (95% CI, 3.1–4.8) for AFA. A significant difference was detected in the median PFS between groups. *HR was calculated using the Cox proportional hazards model, with age, sex and time span of smoking history as covariates and OSI/AFA therapy as the time-dependent factor. With respect to PFS, the results were analysed using the log-rank test (p = 0.014)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us